Trial Profile
3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma: A Phase II Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Isotretinoin (Primary) ; Monoclonal antibody 3F8 (Primary) ; Granulocyte-macrophage colony-stimulating factors
- Indications Cancer metastases; Neuroblastoma
- Focus Therapeutic Use
- 24 Jul 2019 Status changed from active, no longer recruiting to completed.
- 03 Apr 2019 Planned End Date changed from 1 Aug 2019 to 1 Aug 2020.
- 03 Apr 2019 Planned primary completion date changed from 1 Aug 2019 to 1 Aug 2020.